| HOME >> BIOLOGY >> TECHNOLOGY |
Net cash provided by operating
activities $105,834 $70,929 $339,550 $122,735
CASH FLOWS FROM INVESTING
ACTIVITIES:
Purchase of intangible assets (2,900) (7,200) (24,000) (267,336)
Capital expenditures (6,772) (4,046) (18,798) (15,420)
Net cash (used in) investing
activities $(9,672) $(11,246) $(42,798) $(282,756)
CASH FLOWS FROM FINANCING
ACTIVITIES:
Borrowings under bank term
credit facility - - - 240,000
(Repayments) of Senior
Subordinated Notes - (210,000) - (210,000)
(Repayments) under senior
secured credit term loan
facility (92,305) (53,075) (350,511) (468,750)
Borrowings under revolving
credit facilities - - - 84,600
(Repayment) of revolving
credit facilities - - - (84,600)
Proceeds from share capital
issue, net of expenses - - - 1,005,682
Purchase of treasury stock - - - (6,330)
Purchase of preferred stock in
subsidiary - - - (327,164)
Other 157 (54) 71 (455)
Net cash (used in) / provided by
financing activities (92,148) (263,129) (350,440) 232,983
Net increase / (decrease) in
cash and cash equivalents $4,014 $(203,446) $(53,688) $72,962
Cash and cash equivalents,
beginning of period 26,762 287,910 84,464 11,502
Cash and cash equivalents, end
of period $30,776 $84,464 $30,776 $84,464
'/>"/>
| SOURCE Warner Chilcott Limited Copyright©2008 PR Newswire. All rights reserved |